Table 2.
Tolerability and dose endpoints
| Patients in treatment groups |
P-value | ||
|---|---|---|---|
| Bisoprolol | Carvedilol | ||
| (n = 431) | (n = 445) | ||
| Primary endpoint achieveda, no. (%) | 102 (24) | 112 (25) | 0.64 |
| 95% CI for rate | 20–28 | 21–29 | |
| Dose level at follow-up, no. (%) | 0.58 | ||
| 0 (study medication stopped before follow-up) | 46 (11) | 51 (11) | |
| 12.5% (1.25 mg bisoprolol or 3.125 mg carvedilol) | 47 (11) | 45 (10) | |
| 25% (2.5 mg bisoprolol or 6.25 mg carvedilol) | 108 (25) | 97 (22) | |
| 50% (5 mg bisoprolol or 12.5 mg carvedilol) | 98 (23) | 110 (25) | |
| 100% (10 mg bisoprolol or 1–2×25 mg carvedilol) | 132 (31) | 142 (32) | |
aPrimary endpoint achieved: the patient was up-titrated to the guideline-recommended target dose and remained on this dose level until follow-up. The dose was never reduced but delay of titration was allowed.